Trulieve Cannabis (TRLV) Could Be 43% Undervalued Following Its Latest Earnings Report
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- TRLV Trulieve Cannabis
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Trulieve Cannabis belongs to, so it often moves with news about it.
- DFTX Definium Therapeutics-13.3% 30d
Definium Therapeutics is a peer of Trulieve Cannabis in medicinal chemicals and botanical products; rivals often move on the same news.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and is a large health company like Trulieve Cannabis; big names in a sector often move together.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson is a large health company like Trulieve Cannabis; big names in a sector often move together.
- ABBV AbbVie+12.0% 30d
AbbVie is a large health company like Trulieve Cannabis; big names in a sector often move together.
- MRK Merck+3.5% 30d
Merck is a large health company like Trulieve Cannabis; big names in a sector often move together.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| TRLV | +7.11% | +8.08% | base | after close | after close | after close | after close |
| XLV | +0.52% | -0.04% | base | after close | after close | after close | after close |
| DFTX | +14.83% | +9.46% | base | after close | after close | after close | after close |
| LLY | -0.12% | -0.28% | base | after close | after close | after close | after close |
| JNJ | -0.65% | +0.33% | base | after close | after close | after close | after close |
| ABBV | -0.23% | -0.02% | base | after close | after close | after close | after close |
| MRK | +2.39% | +1.67% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Trulieve Cannabis (TRLV) Could Be 43% Undervalued Following Its Latest Earnings Report Yahoo! Finance Canada
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | -0.02% | final price |
| ABBV | five days earlier | -0.23% | final price |
| DFTX | three days earlier | +9.46% | final price |
| DFTX | five days earlier | +14.83% | final price |
| JNJ | three days earlier | +0.33% | final price |
| JNJ | five days earlier | -0.65% | final price |
| LLY | three days earlier | -0.28% | final price |
| LLY | five days earlier | -0.12% | final price |
| MRK | three days earlier | +1.67% | final price |
| MRK | five days earlier | +2.39% | final price |
| TRLV | three days earlier | +8.08% | final price |
| TRLV | five days earlier | +7.11% | final price |
| XLV | three days earlier | -0.04% | final price |
| XLV | five days earlier | +0.52% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 14 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 28 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 41 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 41 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 64 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 90 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Trulieve Cannabis (TRLV) Could Be 43% Undervalued Following Its Latest Earnings Report” scores 12 out of 100. The score uses 1 sources.